Financhill
Buy
57

RAPT Quote, Financials, Valuation and Earnings

Last price:
$1.70
Seasonality move :
-30.45%
Day range:
$1.69 - $1.94
52-week range:
$0.79 - $27.35
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.13x
P/B ratio:
0.62x
Volume:
3.4M
Avg. volume:
5.8M
1-year change:
-93.21%
Market cap:
$59.1M
Revenue:
--
EPS (TTM):
-$2.78

Analysts' Opinion

  • Consensus Rating
    RAPT Therapeutics has received a consensus rating of Hold. The company's average rating is a Hold based on 2 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
  • Price Target Upside
    According to analysts' consensus price target of $6.00, RAPT Therapeutics has an estimated upside of 255.03% from its current price of $1.69.
  • Price Target Downside
    According to analysts, the lowest downside price target is $2.00 representing -18.34% downside risk from its current price of $1.69.

Fair Value

  • According to the consensus of 6 analysts, RAPT Therapeutics has 255.03% upside to fair value with a price target of $6.00 per share.

RAPT vs. S&P 500

  • Over the past 5 trading days, RAPT Therapeutics has overperformed the S&P 500 by 107.81% suggesting its relative strength compared to the major market average is strong at this time.

Share Buyback

  • RAPT Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.

Revenue Growth

  • RAPT Therapeutics has grown year-over-year revenues for 1 quarter straight. In the most recent quarter RAPT Therapeutics reported revenues of --.

Earnings Growth

  • RAPT Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter RAPT Therapeutics reported earnings per share of -$0.47.
Enterprise value:
-38.8M
EV / Invested capital:
--
Price / LTM sales:
20.13x
EV / EBIT:
--
EV / Revenue:
-11.95x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
0.39x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Income Statement
Revenue -- -- -- -- --
Gross Profit -- -- -- -- --
Operating Income -$79.4M -$118.3M -$114.9M -$33.9M -$19.8M
EBITDA -$78.4M -$117.1M -$113.6M -$33.6M -$19.5M
Diluted EPS -$2.55 -$2.88 -$2.78 -$0.82 -$0.47
Period Ending 2020-09-30 2021-09-30 2022-09-30 2023-09-30 2024-09-30
Balance Sheet
Current Assets $125.5M $214.5M $197.9M $187.1M $102.6M
Total Assets $129M $217.5M $209.5M $199.7M $108.5M
Current Liabilities $15.6M $12.7M $13.9M $21.8M $10.4M
Total Liabilities $18.9M $15.6M $20.2M $26.9M $13M
Total Equity $110M $201.9M $189.3M $172.8M $95.5M
Total Debt -- -- -- -- --
Trailing 12 Months Fiscal Quarters
Period Ending 2022-09-30 2023-09-30 2024-09-30 2023-09-30 2024-09-30
Cash Flow Statement
Cash Flow Operations -$68.6M -$92.1M -$100.6M -$21.9M -$17.6M
Cash From Investing -$20.1M $42.2M $74.2M $25.7M $18.4M
Cash From Financing $56.4M $76.3M $10.2M $106K --
Free Cash Flow -$69.8M -$93.3M -$100.8M -$22M -$17.6M
RAPT
Sector
Market Cap
$59.1M
$45.9M
Price % of 52-Week High
6.18%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-93.21%
-32.15%
Beta (5-Year)
0.070
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Technicals

8-day SMA
Buy
Level $1.28
200-day SMA
Sell
Level $3.62
Bollinger Bands (100)
Sell
Level 1.28 - 2.3
Chaikin Money Flow
Sell
Level -48.3M
20-day SMA
Buy
Level $1.16
Relative Strength Index (RSI14)
Buy
Level 62.30
ADX Line
Buy
Level 30.48
Williams %R
Neutral
Level -41.1563
50-day SMA
Buy
Level $1.52
MACD (12, 26)
Buy
Level 0.03
25-day Aroon Oscillator
Buy
Level 8
On Balance Volume
Neutral
Level 149.4M

Financial Scores

--
Altman Z-Score (Annual)
Level (--)
--
CA Score (Annual)
Level (--)
--
Beneish M-Score (Annual)
Level (--)
Sell
Momentum Score
Level (1)
--
Ohlson Score
Level (--)
--
Piotroski F Score (Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)

Revenue Forecast

Earnings per Share Forecast

Company Profile

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

Stock Forecast FAQ

In the current month, RAPT has received 2 Buy ratings 4 Hold ratings, and 0 Sell ratings. The RAPT average analyst price target in the past 3 months is $6.00.

  • Where Will RAPT Therapeutics Stock Be In 1 Year?

    According to analysts, the consensus estimate is that RAPT Therapeutics share price will rise to $6.00 per share over the next 12 months.

  • What Do Analysts Say About RAPT Therapeutics?

    Analysts are divided on their view about RAPT Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that RAPT Therapeutics is a Sell and believe this share price will drop from its current level to $2.00.

  • What Is RAPT Therapeutics's Price Target?

    The price target for RAPT Therapeutics over the next 1-year time period is forecast to be $6.00 according to 6 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.

  • Is RAPT A Buy, Sell Or Hold?

    According to Wall Street analysts, the consensus rating for RAPT Therapeutics is a Hold. 4 of 6 analysts rate the stock a Hold at this time.

  • How Can I Buy Shares Of RAPT?

    You can purchase shares of RAPT Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase RAPT Therapeutics shares.

  • What Is The RAPT Therapeutics Share Price Today?

    RAPT Therapeutics was last trading at $1.70 per share. This represents the most recent stock quote for RAPT Therapeutics. Yesterday, RAPT Therapeutics closed at $1.69 per share.

  • How To Buy RAPT Therapeutics Stock Online?

    In order to purchase RAPT Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will Tesla Go Up or Down in 2025?
Will Tesla Go Up or Down in 2025?

The last few months have been exciting for Tesla and…

Why Is Coinbase Stock Going Down?
Why Is Coinbase Stock Going Down?

Every way you look at it, Coinbase has had a…

Is Uber Stock a Buy on the Dip?
Is Uber Stock a Buy on the Dip?

Shares of Uber Technologies (NYSE:UBER) have been fading fast in…

Stock Ideas

Buy
64
Is AAPL Stock a Buy?

Market Cap: $3.9T
P/E Ratio: 42x

Buy
52
Is NVDA Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 115x

Buy
54
Is MSFT Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 36x

Alerts

Sell
50
LMND alert for Dec 28

Lemonade [LMND] is down 10.69% over the past day.

Sell
50
TSLL alert for Dec 28

Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.

Buy
63
SMLR alert for Dec 28

Semler Scientific [SMLR] is down 9.65% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock